NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.29
-0.18 (-5.19%)
▼
5d:
-4.64%
30d:
-4.08%
90d:
-28.63%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
20d
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NAGE this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 13.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NAGE shows positive signals but monitor for confirmation. Market pricing in 13.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.07
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.25
47.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.29, which is considered fair relative to its 30-day fair value range of $3.34 to $3.49. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.6) compared to its historical average (18.2). Remarkably, the market is currently pricing in an annual earnings decline of 13.9% over the next few years. This pessimistic expectation contrasts with the company's recent 16.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+264.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.00 (+264.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.34 -
$3.49
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 264.7% below Wall St target ($12.00)
Trading Range Analysis
30-Day Trading Range
$3.34 -
$3.49
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.35
Resistance Level
$4.03
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.58
Wall Street Target
$12.00
(+264.7%)
Revenue Growth (YoY)
3.3%
Earnings Growth (YoY)
16.7%
Profit Margin
14.3%
Valuation Discount vs History
-13.9% cheaper
PE vs Historical
11.6 vs 18.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.9%
(market-implied from PE analysis)
1-Year Target
$2.96
(-10%)
2-Year Target
$2.66
(-19%)
3-Year Target
$2.40
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→18)
$3.77
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 25.3%)
$12.16
(+270%)
Base:
(SPY PE: 11.6, Growth: 25.3%)
$6.47
(+97%)
Bear:
(PE: 9.8, Growth: 25.3%)
$5.50
(+67%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 16.52 | Current EPS (TTM): $0.21
Bull Case
$5.16
(+57%)
Analyst growth 35.2%, PE expands to 18.2
Base Case
$4.69
(+43%)
Market implied 35.2%, PE stable at 16.5
Bear Case
$2.36
(-28%)
Severe decline -20.0%, PE contracts to 14.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.6 to 18.2
Stabilization Target:
$5.17
(+57.1%)
PE Expansion Potential:
+57.1%
Share & Embed Analysis
Last updated: July 15, 2026 1:09 AM ET
Data refreshes hourly during market hours. Next update: 2:09 AM
Data refreshes hourly during market hours. Next update: 2:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
